Methods of treatment using cholestosome vesicles for incorporation of molecules into chylomicrons
AssigneeTherasyn Sensors, Inc.
InventorsJerome J. Schentag, Mary P. McCourt, Lawrence Mielnicki, Julie Hughes
Life of this patent
Estimating the term…
Loading patent…
AssigneeTherasyn Sensors, Inc.
InventorsJerome J. Schentag, Mary P. McCourt, Lawrence Mielnicki, Julie Hughes
Estimating the term…
The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
A method of treating a patient or subject in need of treatment of a disease state or condition comprising administering to said patient or subject a composition comprising one or more active molecules encapsulated in a liquid vesicle to provide an intact loaded vesicle wherein the outer surface coating of said loaded vesicle comprises at least one cholesteryl ester obtained from cholesterol and a C6-C26 fatty acid, said molecules obtaining in an effective amount an intracellular concentration in target cells of said patient or subject which is at least 2-fold greater than the concentration obtained by said molecules in the absence of said coating, wherein said molecules are selected from the group consisting of small molecules, proteins, monoclonal antibodies, peptides, polynucleotides, oligonucleotides, nucleic acids and mixtures thereof, wherein said administration includes at least one oral, parenteral or topical dosage form and said outer surface coating of said loaded vesicle remains intact during passage of said loaded vesicle across a membrane of a cell in said patient or subject and wherein said vesicle optionally releases said one or more molecules inside target cells by the action of cholesteryl ester hydrolases on said vesicle, and said disease state or condition is Alzheimer's disease, arthritis, Crohn's disease, pancreatic cancer, melanoma, hyperlipidemia, a Hepatitis C virus infection, psoriasis, pulmonary arterial hypertension (PAH), eosinophilic asthma, an intracellular bacterial or fungal infection, metabolic syndrome or type 2 diabetes mellitus, a condition requiring initiation or increase of growth or a condition requiring a vaccine in said patient or subject.
Dependencies are inferred from the claim text.